Sublicensed Technology. Amgen shall timely perform and discharge its obligations under the Existing License during the Term and shall not permit any action to be taken or event to occur, in each case, within Amgen's reasonable control, which would give Existing Licensor the right to terminate Existing License. InterMune agrees that the rights granted under this Agreement are subject to, and agrees to be bound by, all the terms and conditions required of sublicensees under the Existing License.
Appears in 2 contracts
Sources: License and Commercialization Agreement (Intermune Inc), License and Commercialization Agreement (Valeant Pharmaceuticals International)